NY-PHILIP-MORRIS-INTL
19.9.2022 14:02:31 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) is calling on policymakers, regulators, public health advocates, tobacco companies, and activists to unite behind bringing about the end of cigarette smoking.
As the United Nations General Assembly (UNGA) convenes to discuss global challenges, the company is releasing a white paper, Rethinking Disruption: Innovating for Better in an Era of Division, which previews select findings from a new international survey highlighting the broad societal support for disruptive innovations to improve public health and address other critical issues. The white paper explores how the world’s most significant challenges—including smoking—can be solved through pragmatic solutions and decisive, concerted action.
The survey respondents (17,207 adults aged 21 and older in 14 countries) believe that the development and adoption of new technologies, innovations, and capabilities can enable significant progress against a range of issues over the next 10 to 20 years, including:
- Encouraging healthier eating habits (78 percent)
- Ensuring quality and affordable healthcare for all (72 percent)
- Reducing smoking rates (65 percent)
- Eliminating hunger and malnourishment (62 percent)
“We believe that there exists a real opportunity for activists, public health leaders, and policymakers to significantly improve public health by helping millions of adults who would otherwise continue to smoke switch to better alternatives,” said Jacek Olczak, CEO, PMI. “For more than a decade, PMI has been transforming for good, directing our resources and energy to provide better options to adult smokers and deliver a smoke-free future as quickly as possible. Though the best choice is never to start smoking or to quit if you do, we know that, realistically, many smokers will not quit—and, frankly, those adults deserve better.”
Senior PMI executives, including Jacek Olczak, will address international forums during the week of September 19, talking about the pressing need for collaboration on solutions that are real, practical, and grounded in science to achieve meaningful progress in the tobacco sector and beyond.
Events include:
- September 20: CEO Jacek Olczak will address the 2022 Concordia Annual Summit on the topic of “Driving Change in the Age of Disruption.”
- September 20: SVP, External Affairs Grégoire Verdeaux will join the Diplomatic Courier for a panel discussion on “The Global Goals in Action 2022: Reduced Inequalities.”
- September 21: Deepak Mishra, President, Americas Region, will join Recount Media for a breakfast panel titled, “From Disruption to Progress—Innovating for Better in the Age of Division.”
- September 22: CEO Jacek Olczak will be a panelist at a custom event with the Wall Street Journal on “Disruption 2.0: Build Up Not Break Down.”
- September 22: CEO Jacek Olczak will participate in the Leaders on Purpose CEO Summit, addressing the “Transition on Purpose: Leading Systemic Business Model Transformation in Times of Disruption.”
Today, better alternatives to continued smoking exist and can bring about radical, positive change for public health—creating a future in which cigarettes are obsolete. Real-world evidence shows that providing adult smokers access to these innovative, scientifically substantiated smoke-free products—while protecting youth and nonsmokers—is an effective tool in reducing smoking rates. By embracing this opportunity for meaningful tobacco harm reduction, governments, public health authorities, and civil society can harness the power of science and innovation to achieve disruptive change that benefits adults who smoke and the public health.
“Innovation is a crucial piece of the solution of eliminating cigarettes, but it’s not the only piece,” said Grégoire Verdeaux, Senior Vice President, External Affairs, PMI. “Once scientific and technological advances have been made, regulations need to keep up. Policies should reflect that certain tobacco and nicotine products are less harmful and ensure that adult smokers who do not quit can access and afford these better alternatives to cigarettes. This is especially true in developing countries, where most smokers are.”
To learn more about how PMI is delivering a smoke-free future faster, visit PMI.com/rethinkdisruption.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free products were available for sale in 70 markets, and PMI estimates that approximately 13.2 million adults around the world had already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005428/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
